Direct oral anticoagulants in oncology in clinical praxis
| Autor: | Juraj Sokol, Martin Péč, Marián Mokáň, Marianna Kubašková, František Kovář, Michal Mokáň, Frantisek Nehaj |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Deep vein Peripheral edema Administration Oral Hemorrhage Disease Internal medicine Neoplasms Internal Medicine medicine Humans Venous Thrombosis business.industry Cancer Anticoagulants Heparin Venous Thromboembolism Heparin Low-Molecular-Weight medicine.disease Thrombosis medicine.anatomical_structure Phlegmasia alba dolens medicine.symptom Cardiology and Cardiovascular Medicine business Venous thromboembolism medicine.drug |
| Zdroj: | Vnitrni lekarstvi. 65(1) |
| ISSN: | 0042-773X |
| Popis: | Relation between oncological diseases and venous thrombo-embolism (VTE) is well known for almost 2 centuries. In 1823 Bouillaud assumed by three patients with tumor and recent deep vein thrombosis (DVT), that peripheral edema of lower limbs emerges as a result of#8222;obturation#8220; of veins by#8222;fibrinous coagulum#8220; (caillot fibrineux), which was induced by oncological disease. French physician Armand Trousseau wrote about this relation in his book#8222;Phlegmasia alba dolens#8221; again in the year 1865. Many studies were developed in times of Bouillaud a Trousseau, which just confirmed existence of relation between tumor and VTE. Oncological disease presents a significant risk factor of formation of VTE. Recent references favorising the use of light molecular weight heparin (LMWH) in long-term anticoagulation therapy of patients with cancer. Recently we have just few clinical data about efficiency and safety of direct oral anticoagulants (DOACs) in oncological patients, however many meta-analysis of clinical studies has shown benefit of therapy with DOACs towards conventional therapy. Key words: direct oral anticoagulants (DOACs) - oncology - venous thromboembolism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|